In this Issue:
Pentoxifylline: no benefit in severe alcoholic hepatitis
Bariatric surgery: first-line therapy in NASH?
Lifestyle intervention improves cirrhotic portal hypertension
CAC score predicts obstructive CAD in cirrhotics
3D+RBV regimen: high SVR12 rates in HCV GT1 patients
Younger age in PBC: greater symptom burden . . .
. . . and significant cognitive impairment
NVR 3-778 (HBV core inhibitor) looks promising
HCV eradication may improve brain function
Aspirin use related to lower liver fibrosis indices
Galectin-3 inhibitor GR-MD-02 promising in NASH + advanced fibrosis
Please login below to download this issue (PDF)